Tempest Therapeutics Inc (TPST)

$2.26 -0.03 (-1.31%)
Market Cap 11.14M
Revenue (ttm) 0.00
Net Income (ttm) -41.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 46,800
Avg Vol 109,966
Day's Range N/A - N/A
Shares Out 4.93M
Stochastic %K 38%
Beta -2.42
Analysts Strong Sell
Price Target $10.50

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
Yi_YandH
Yi_YandH Mar. 15 at 8:32 PM
$TPST $ICU
0 · Reply
lousjamsession
lousjamsession Mar. 13 at 11:41 PM
$TPST TPST has the possibility of a regional partnership for TPST-1120, especially in Asia where liver cancer rates are much higher. Biotechs sometimes go quiet during negotiations because any new data can affect deal terms. If a partner steps in with upfront cash and milestone funding, the market could suddenly realize TPST isn’t just a small trial company anymore. This can create a period where the stock feels pinned or inactive, even though things may be happening behind the scenes. For a small biotech, even a $50M–$150M upfront payment can dramatically change the financial runway and market perception.
1 · Reply
Michl2000
Michl2000 Mar. 13 at 10:34 PM
$TPST 😭😭😭
1 · Reply
lousjamsession
lousjamsession Mar. 13 at 9:19 PM
$TPST
1 · Reply
SuperGreenToday
SuperGreenToday Mar. 13 at 11:58 AM
$TPST
1 · Reply
lousjamsession
lousjamsession Mar. 13 at 12:26 AM
$TPST still looks like it’s barcoding. Even after the recent news, price stayed stuck in a tight range around the low $2.30s with very little expansion in volatility. That usually means market makers are keeping the price pinned while volume stays light and the market waits for the next real catalyst. Until buying pressure increases or new information hits, it’s common for small-cap biotech stocks like Tempest Therapeutics (TPST) to trade in these narrow bands. In my opinion this looks more like consolidation and positioning than a true rejection of the news.
1 · Reply
Michl2000
Michl2000 Mar. 12 at 9:47 PM
$TPST looking at the facts concerning all TPST drugs: N o t h i n g positive - just hopium. Exactly this is represented by the share price.
2 · Reply
josegodoy
josegodoy Mar. 12 at 9:17 PM
$TPST $2.24 & $2.13 are number we don’t wanna see (but…..)
0 · Reply
Xamayca
Xamayca Mar. 12 at 8:33 PM
$TPST simply following market sentiment today
0 · Reply
Michl2000
Michl2000 Mar. 12 at 2:09 PM
$TPST 1.98$ end of the week???
0 · Reply
Latest News on TPST
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Mar 11, 2026, 8:00 AM EDT - 4 days ago

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Feb 25, 2026, 7:59 AM EST - 18 days ago

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Feb 11, 2026, 6:59 AM EST - 4 weeks ago

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

Feb 4, 2026, 4:47 PM EST - 5 weeks ago

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Jan 20, 2026, 5:20 PM EST - 7 weeks ago

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 26, 2025, 4:05 PM EST - 3 months ago

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 25, 2025, 8:00 AM EST - 3 months ago

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

Nov 19, 2025, 9:00 AM EST - 4 months ago

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

BTX

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 8:30 AM EST - 4 months ago

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:12 PM EDT - 7 months ago

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Jun 30, 2025, 8:00 AM EDT - 9 months ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Jun 11, 2025, 8:00 AM EDT - 9 months ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Jun 5, 2025, 8:00 AM EDT - 10 months ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:28 PM EDT - 10 months ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 28, 2025, 4:05 PM EDT - 11 months ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 21, 2025, 8:00 AM EDT - 11 months ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Apr 9, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 27, 2025, 4:10 PM EDT - 1 year ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Mar 13, 2025, 8:00 AM EDT - 1 year ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 10, 2025, 8:00 AM EST - 1 year ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:30 PM EST - 1 year ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Jan 6, 2025, 8:00 AM EST - 1 year ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 4:30 PM EST - 1 year ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:21 PM EST - 1 year ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Oct 10, 2024, 9:06 AM EDT - 1 year ago

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Oct 10, 2024, 7:01 AM EDT - 1 year ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2024, 4:30 PM EDT - 1 year ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 15, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:56 PM EDT - 1 year ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Jun 20, 2024, 9:43 AM EDT - 1 year ago

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Jun 18, 2024, 6:22 PM EDT - 1 year ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

May 31, 2024, 3:45 PM EDT - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:29 PM EDT - 2 years ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Apr 17, 2024, 1:26 PM EDT - 2 years ago

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 2 years ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:25 PM EDT - 2 years ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 2 years ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 8:00 AM EST - 2 years ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 5:17 PM EST - 2 years ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Tempest Therapeutics shares end wild week with 8% drop

Oct 13, 2023, 4:13 PM EDT - 2 years ago

Tempest Therapeutics shares end wild week with 8% drop

Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 12:49 PM EDT - 2 years ago

Tempest Therapeutics shares head back to earth after 4,000% gain

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Oct 11, 2023, 12:29 PM EDT - 2 years ago

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Tempest Adopts Limited Duration Stockholder Rights Plan

Oct 11, 2023, 8:01 AM EDT - 2 years ago

Tempest Adopts Limited Duration Stockholder Rights Plan

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Oct 10, 2023, 4:05 PM EDT - 2 years ago

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Yi_YandH
Yi_YandH Mar. 15 at 8:32 PM
$TPST $ICU
0 · Reply
lousjamsession
lousjamsession Mar. 13 at 11:41 PM
$TPST TPST has the possibility of a regional partnership for TPST-1120, especially in Asia where liver cancer rates are much higher. Biotechs sometimes go quiet during negotiations because any new data can affect deal terms. If a partner steps in with upfront cash and milestone funding, the market could suddenly realize TPST isn’t just a small trial company anymore. This can create a period where the stock feels pinned or inactive, even though things may be happening behind the scenes. For a small biotech, even a $50M–$150M upfront payment can dramatically change the financial runway and market perception.
1 · Reply
Michl2000
Michl2000 Mar. 13 at 10:34 PM
$TPST 😭😭😭
1 · Reply
lousjamsession
lousjamsession Mar. 13 at 9:19 PM
$TPST
1 · Reply
SuperGreenToday
SuperGreenToday Mar. 13 at 11:58 AM
$TPST
1 · Reply
lousjamsession
lousjamsession Mar. 13 at 12:26 AM
$TPST still looks like it’s barcoding. Even after the recent news, price stayed stuck in a tight range around the low $2.30s with very little expansion in volatility. That usually means market makers are keeping the price pinned while volume stays light and the market waits for the next real catalyst. Until buying pressure increases or new information hits, it’s common for small-cap biotech stocks like Tempest Therapeutics (TPST) to trade in these narrow bands. In my opinion this looks more like consolidation and positioning than a true rejection of the news.
1 · Reply
Michl2000
Michl2000 Mar. 12 at 9:47 PM
$TPST looking at the facts concerning all TPST drugs: N o t h i n g positive - just hopium. Exactly this is represented by the share price.
2 · Reply
josegodoy
josegodoy Mar. 12 at 9:17 PM
$TPST $2.24 & $2.13 are number we don’t wanna see (but…..)
0 · Reply
Xamayca
Xamayca Mar. 12 at 8:33 PM
$TPST simply following market sentiment today
0 · Reply
Michl2000
Michl2000 Mar. 12 at 2:09 PM
$TPST 1.98$ end of the week???
0 · Reply
fantastex
fantastex Mar. 12 at 1:58 PM
$TPST any news on the warrants ? I didn't get them yet. (etoro)
1 · Reply
fantastex
fantastex Mar. 12 at 1:57 PM
$TPST if I had money, I would buy at this level...but! I m waiting for my warrants still🤔🤔
0 · Reply
josegodoy
josegodoy Mar. 12 at 1:43 PM
$TPST hmmm…. Chalkin money flow (CMF) - 3 year view Parabolic SAR 20 moving average (EMA) Pivot Hmmmmm
1 · Reply
SuperGreenToday
SuperGreenToday Mar. 12 at 12:20 PM
$TPST
0 · Reply
brunoq14
brunoq14 Mar. 12 at 7:10 AM
$TPST Having taken full loss, may reenter as modest speculation.
0 · Reply
Xamayca
Xamayca Mar. 12 at 3:18 AM
$TPST 25 patients are considered sufficient for phase I or early phase II studies focused on safety . I also would like to offer my 2cents on the supposed lack of excitement due to the study being based in China. I’m willing to bet that if a Chinese licensing deal or sale of either of the two legacy TPST molecules comes to pass the excitement level ratchets up dramatically over those Chinese patient results”
2 · Reply
claybridge
claybridge Mar. 11 at 8:50 PM
$TPST
0 · Reply
Michl2000
Michl2000 Mar. 11 at 8:44 PM
$TPST biggest 💩 ever. 🙅
0 · Reply
joeyknowie
joeyknowie Mar. 11 at 7:53 PM
$TPST from today’s PR: “ As of the data cutoff, all six efficacy evaluable patients enrolled in the REDEEM-1 trial had achieved a complete response (CR) according to the International Myeloma Working Group (IMWG) uniform response criteria. Among 25 evaluable patients with measurable disease at baseline across both studies, the overall response rate (“ORR”) was 100% (25/25). Tempest plans to present the results of the REDEEM-1 trial and updated results from the IIT at a scientific meeting later this year.” What gives? The news seems amazing to me unless 25 patients is too small a sample size but 100% on 25 people seems excellent to me.
2 · Reply
lousjamsession
lousjamsession Mar. 11 at 4:45 PM
$TPST
0 · Reply
lousjamsession
lousjamsession Mar. 11 at 4:44 PM
$TPST Interesting that the company released news but the stock barely moved. The chart looks like classic barcoding / price pinning, trading in a very tight range with low volume. When that happens it’s usually one of three things: the news was already priced in, market makers keeping it in a narrow band, or quiet accumulation happening. With a market cap this small, it likely won’t take much volume or a real catalyst to break the range. For now it looks like consolidation while the market waits for the next meaningful update.
1 · Reply
Michl2000
Michl2000 Mar. 11 at 3:59 PM
$TPST 💩💩💩
0 · Reply